Mark DuBois - Asarina Pharma Communications Mang
Insider
Mark DuBois is Communications Mang of Asarina Pharma AB
| Phone | 46 8 52 48 44 82 |
| Web | https://www.asarinapharma.com |
Asarina Pharma Management Efficiency
The company has return on total asset (ROA) of (0.4555) % which means that it has lost $0.4555 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.7014) %, meaning that it generated substantial loss on money invested by shareholders. Asarina Pharma's management efficiency ratios could be used to measure how well Asarina Pharma manages its routine affairs as well as how well it operates its assets and liabilities.The company has accumulated 5.3 M in total debt. Asarina Pharma AB has a current ratio of 17.74, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Asarina Pharma until it has trouble settling it off, either with new capital or with free cash flow. So, Asarina Pharma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Asarina Pharma AB sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Asarina to invest in growth at high rates of return. When we think about Asarina Pharma's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Thoas MD | Cantargia AB | 61 | |
| Gunilla Osswald | BioArctic AB | 62 | |
| Kjell Sjstrm | Cantargia AB | N/A | |
| Frida Lekander | BioArctic AB | N/A | |
| Carl MD | Ascelia Pharma AB | 60 | |
| Tomas Andersson | Biovica International AB | 63 | |
| Ignacio GarciaRibas | Cantargia AB | N/A | |
| Henrik DVM | Biovica International AB | 57 | |
| Marcuss | Cantargia AB | N/A | |
| Mattias Bergqvist | Biovica International AB | 53 | |
| Johanna Flting | BioArctic AB | 51 | |
| Pr Gellerfors | BioArctic AB | 76 | |
| Adnan Deronic | Cantargia AB | N/A | |
| Otti Gref | Biovica International AB | 55 | |
| Anders Rylander | Biovica International AB | 53 | |
| Mathias Skalmstad | Sprint Bioscience AB | N/A | |
| Mikael Widell | Ascelia Pharma AB | 65 | |
| Johanna Christensen | Cantargia AB | N/A | |
| Prof MBA | Sprint Bioscience AB | 64 | |
| Despina Hedin | Ascelia Pharma AB | 37 | |
| Nina Valkama | Cantargia AB | N/A | |
Management Performance
| Return On Equity | -0.7 | |||
| Return On Asset | -0.46 |
Asarina Pharma AB Leadership Team
Elected by the shareholders, the Asarina Pharma's board of directors comprises two types of representatives: Asarina Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Asarina. The board's role is to monitor Asarina Pharma's management team and ensure that shareholders' interests are well served. Asarina Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Asarina Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Otto MSc, Chief Officer | ||
| Torbjrn MD, Chief Board | ||
| Peter Nordkild, CEO Officer | ||
| MBA MSc, Chief Officer | ||
| Mark DuBois, Communications Mang | ||
| Karin Ekberg, Chief Officer |
Asarina Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Asarina Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.7 | |||
| Return On Asset | -0.46 | |||
| Current Valuation | 10.34 M | |||
| Shares Outstanding | 22.64 M | |||
| Shares Owned By Insiders | 38.91 % | |||
| Shares Owned By Institutions | 31.91 % | |||
| Price To Book | 1.17 X | |||
| EBITDA | (37.52 M) | |||
| Net Income | (31.66 M) | |||
| Cash And Equivalents | 21.71 M |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Asarina Pharma in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Asarina Pharma's short interest history, or implied volatility extrapolated from Asarina Pharma options trading.
Pair Trading with Asarina Pharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Asarina Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Asarina Pharma will appreciate offsetting losses from the drop in the long position's value.Moving against Asarina Stock
| 0.64 | KAR | Karnov Group AB | PairCorr |
| 0.56 | XSPRAY | XSpray Pharma AB | PairCorr |
| 0.52 | PIERCE | Pierce Group AB | PairCorr |
| 0.45 | EGTX | Egetis Therapeutics Earnings Call Next Week | PairCorr |
The ability to find closely correlated positions to Asarina Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Asarina Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Asarina Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Asarina Pharma AB to buy it.
The correlation of Asarina Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Asarina Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Asarina Pharma AB moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Asarina Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Asarina Pharma AB. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.
Complementary Tools for Asarina Stock analysis
When running Asarina Pharma's price analysis, check to measure Asarina Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Asarina Pharma is operating at the current time. Most of Asarina Pharma's value examination focuses on studying past and present price action to predict the probability of Asarina Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Asarina Pharma's price. Additionally, you may evaluate how the addition of Asarina Pharma to your portfolios can decrease your overall portfolio volatility.
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Stocks Directory Find actively traded stocks across global markets | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk |